It is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase in the gastric parietal cell.
Symptomatic erosive or GORD active duodenal Ulcer, active bening ulcer, H-Pylori positive duodenal ulcers.
Hypersensitivity to any component of the formulations.
Oesophageal or gastric malignancy should be excluded prior to commencing treatment of rabeprazole, treatment should be stopped immediately at the recurrence of skin lesions.
Diarrhoea, dyspepsia, asthenia, flatulence, non-specific pain eructation, leg cramps, UT infections, abdominal pain, Flu syndrome, dysuria.
Ketoconazole level reduce by 1/3 , if Co-administered with rabeprazole.
Adults/Elderly: Active duodenal ulcer and active benign gastric ulcer: 20 mg be taken once daily in the morning. Some patients with active duodenal ulcer may respond to one 10 mg tablet to be taken once daily in the morning.
Erosive or uncerative gastro-oesophageal reflux disease (GORD): 20 mg be taken once daily can be used.
Eradication of H-pylori: It is indicated for H-pylori positive duodenal ulcers, as part of the eradications programme with appropriate antibiotics.